SCHEMBL18259581

SCHEMBL18259581

CC(C)(C)OC(=O)N1CCOC(CCCCC(=O)O)C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RECQL P46063 1/20 0.40
NR1H2 P55055 1/20 0.37
EPHA2 P29317 4/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
FAAH O00519 1/20 0.36
PDK1 Q15118 2/20 0.36
ERBB2 P04626 1/20 0.36
EPHB4 P54760 1/20 0.36
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
USP30 Q70CQ3 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18259580 1.00 USP2 (0.44) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL18259594 0.91 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL18259593 0.91 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL31479278 0.91 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL18259367 0.86 RAB9A (0.43) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL18259368 0.86 RAB9A (0.43) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL18259604 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL20516006 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL8891920 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2EPHA2
SCHEMBL23807798 0.85 USP2 (0.44) USP2SMN1; SMN2RECQLNR1H2EPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122747-B1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) 2020-05-20 EP disclosed
US-9771358-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-09-26 US disclosed
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS DPYD, SLC10A1, HPRT1 USP2 4117/4885SMN1; SMN2 1778/4885RECQL 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.